MARKET

CDTX

CDTX

Cidara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.160
0.000
0.00%
After Hours: 3.220 +0.06 +1.90% 16:43 02/21 EST
OPEN
3.170
PREV CLOSE
3.160
HIGH
3.240
LOW
3.080
VOLUME
154.71K
TURNOVER
--
52 WEEK HIGH
4.440
52 WEEK LOW
1.223
MARKET CAP
128.02M
P/E (TTM)
-2.2770
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CDTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CDTX stock price target is 6.88 with a high estimate of 10.00 and a low estimate of 5.00.

EPS

CDTX News

More
  • Cidara Therapeutics (CDTX) Investor Presentation - Slideshow
  • Seeking Alpha - Article · 1d ago
  • Cidara Therapeutics to Present at Transplantation & Cellular Therapy (TCT) and Mycology 2020 Medical Conferences
  • GlobeNewswire · 4d ago
  • Cidara Therapeutics Announces Closing of Rights Offering
  • GlobeNewswire · 02/12 22:30
  • Some Cidara Therapeutics (NASDAQ:CDTX) Shareholders Have Taken A Painful 74% Share Price Drop
  • Simply Wall St. · 02/11 11:25

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About CDTX

Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.
More

Webull offers kinds of Cidara Therapeutics Inc stock information, including NASDAQ:CDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDTX stock news, and many more online research tools to help you make informed decisions.